

Public Health

## Opting for COVID-19 Vaccine Yes versus No

David Han\*

The California State University in Los Angeles, 5151 State University Dr., Los Angeles, CA 90032, USA

\*: All correspondence should be sent to: Dr. David Han

Author's Contact: Dr. David Han, Ph.D., E-mail: [davidhan-csula@gmail.com](mailto:davidhan-csula@gmail.com)

DOI: <https://doi.org/10.15354/si.24.ed085>

Funding: No funding source declared.

COI: The author declares no competing interest.


AI Declaration: The author affirms that artificial intelligence did not contribute to the process of preparing the work.

**The COVID-19 vaccine has unquestionably provided a multitude of advantages in the fight against the global pandemic. The virus has resulted in a substantial decrease in infection rates, hospitalizations, and fatalities as a result of its successful development and distribution. Individuals can contribute to the collective effort to attain herd immunity and end the spread of COVID-19 by receiving the vaccine, which will protect them and those around them. Nevertheless, it is crucial to recognize a few of the vaccine's downsides. These may encompass temporary side effects, such as muscle soreness or fatigue, as well as concerns regarding the long-term effectiveness and potential unforeseen risks. The COVID-19 vaccine is a critical weapon in the fight against this unprecedented public health crisis, as the benefits of receiving it far outweigh any potential risks, despite the drawbacks.**

**Keywords:** COVID-19; Vaccine; Pandemic; Benefits versus Drawbacks; Immunity

Science Insights, 2024 September 30; Vol. 45, No. 3, pp.1491-1495.

© 2024 Insights Publisher. All rights reserved.



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the [Creative Commons Attribution-NonCommercial 4.0 License](https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed by the Insights Publisher.

**T**HE COVID-19 pandemic has resulted in an unparalleled public health catastrophe, with millions of individuals worldwide becoming sick and incalculable others succumbing to the infectious disease (Böhmwald et al., 2024; Chen et al., 2022; Rodríguez - Morales et al., 2023; Zheng et al., 2023). The rapid acceleration of the development and distribution of COVID-19 vaccinations in reaction to the worldwide crisis has provided optimism for the resolution of the pandemic (Hartner et al., 2024; Kashte et al., 2021). Notwithstanding the accessibility of vaccinations, there exists a portion of the populace that exhibits reluctance in obtaining the vaccine.

An essential rationale for choosing the COVID-19 vac-

ination is its provision of immunity against the virus, therefore diminishing the likelihood of serious disease, hospitalization, and mortality (Park et al., 2024; Srivastava et al., 2024). The vaccines have demonstrated remarkable effectiveness in clinical trials, exhibiting significant rates of efficacy in the prevention of COVID-19 infection (Del Cura-Bilbao et al., 2022; Hò et al., 2024; Mohammed et al., 2022; Rahmani et al., 2022; Shi et al., 2023; Wu et al., 2023). The administration of the vaccine enables individuals to contribute to the development of herd immunity throughout their communities, therefore impeding the transmission of the virus and safeguarding those who are most susceptible to serious illness (Krammer, 2023; Marks & Califf,

2024; Rana et al., 2023; Shi et al., 2023).

One further persuasive rationale for choosing the COVID-19 vaccine is its potential to effectively terminate the epidemic and reinstate a state of normalcy within civilization (Cankat et al., 2023; Rashi, 2023; Stoddard et al., 2021; Zhang et al., 2024). Previous immunization campaigns have effectively managed and eliminated contagious diseases, including smallpox and polio (Artenstein & Grabenstein, 2008; Hinman, 1999; Orenstein & Ahmed, 2017). Through the attainment of extensive immunization coverage, it is possible to anticipate a stage where the virus ceases to pose a substantial risk to public health, so enabling the restoration of normal activities and the reopening of commercial establishments and educational institutions.

Moreover, the administration of the COVID-19 vaccination can serve to safeguard vulnerable members of the community who may be more susceptible to severe disease or complications resulting from the virus (Jamaludin et al., 2020; Mazidimoradi et al., 2023; Šalamon et al., 2024; Seyedin et al., 2020). Administering vaccinations to individuals can effectively mitigate the overall strain on healthcare systems and impede the transmission of the virus to susceptible groups, such as the elderly or those with pre-existing health disorders (Adler et al., 2024; Mostafa & Moustafa, 2024; Pietzner et al., 2024). Therefore, choosing to receive the vaccination can be regarded as a demonstration of social duty, so making a positive contribution to the overall welfare of society.

Conversely, there are certain issues and arguments that should be considered while considering the decision to have the COVID-19 vaccine. A primary factor contributing to the reluctance of some individuals to get the vaccine is their apprehensions regarding possible adverse reactions or enduring health hazards (Afrashtehfar et al., 2023; Cerda & Garc ía, 2021). Although the vaccinations have been subjected to thorough testing and have demonstrated safety and efficacy in clinical trials, there remains some ambiguity regarding the long-term impacts of the vaccines. This is because they are relatively recent, and the complete range of their safety profile may not yet be ascertainable.

There exist apprehensions and misunderstandings regarding the progress and dissemination of the COVID-19 vaccines. Some have voiced doubt over the rapidity of the vaccine development and their reservations about the participation of pharmaceutical companies in the vaccine implementation (Chakraborty et al., 2023; Kashte et al., 2021; Mead et al., 2024). Furthermore, there have been documented instances of infrequent, yet severe adverse effects linked to some vaccinations, such as thrombosis or hypersensitivity responses, which have prompted inquiries into the general safety of the vaccines (Faksov áet al., 2024; Polykretis et al., 2023).

Another compelling reason against choosing the COVID-19 vaccination is the concept of personal choice and autonomy, since some persons assert their entitlement to determine whether or not to get the vaccine (Afrashtehfar et al., 2023; Alazzam et al., 2022; Iserson, 2020; Prasad & Haslam, 2024). Considerable apprehension exists regarding the possible encroachment upon personal freedoms and the concept of compulsory immunization, since some individuals believe they should have the autonomy to determine their own health and welfare without government interference (Patryn & Zagaja, 2016).

Moreover, individuals' decisions about vaccination might be influenced by cultural and religious views, leading certain communities to express concerns about vaccines rooted in their own values and traditions (Alsuwaidi et al., 2023; Machekanyanga et al., 2017; Mao et al., 2024; Unfried & Priebe, 2024; Yoder & Dworkin, 2006). It is crucial to recognize and honor the many viewpoints and convictions that influence people's views on vaccination, and to participate in substantive discussions and educational activities to tackle concerns and debunk false information.

The choice to use the COVID-19 vaccine is a very individual one that should be grounded on a meticulous evaluation of the possible advantages and drawbacks of immunization. Although there are persuasive reasons to endorse the vaccination, such as its efficacy in protecting against the virus and its positive impact on public health, there are also legitimate worries and misgivings that individuals may have regarding the immunizations. Efficient and transparent discussions on vaccination among politicians, healthcare practitioners, and communities are crucial to ensure the provision of precise information and assistance to enable individuals to make well-informed choices regarding their health (Goldin et al., 2024; Koneru et al., 2024; Prasad & Haslam, 2024). Effective collaboration to attain extensive immunization coverage is crucial in surmounting the COVID-19 epidemic and restoring a state of normalcy.

In spite of the challenges, the advantages of COVID-19 vaccines significantly exceed any prospective disadvantages. Vaccination continues to be the most effective method available for preventing the spread of the virus, preventing severe illness and mortality, and putting an end to the pandemic. It is essential that we continue to prioritize vaccination initiatives, resolve obstacles to access and uptake, and collaborate to guarantee that all individuals have access to lifesaving vaccines. This opportunity to construct a more resilient and healthier world for all must be capitalized on, as the development and distribution of COVID-19 vaccines have been a remarkable accomplishment in the fight against the pandemic. ■

## References

- Adler, J. M., Vidal, R. M., Langner, C., Vladimirova, D., Abdelgawad, A., Kunecova, D., Lin, X., Nouailles, G., Voss, A., Kunder, S., Gruber, A. D., Wu, H., Osterrieder, N., Kunec, D., & Trimpert, J. (2024). An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission. *Nature Communications*, 15(1). DOI: <https://doi.org/10.1038/s41467-024-45348-2>
- Afrashtehfar, K. I., Jurado, C. A., Abu-Fanas, S. H., & Jaber, M. A. (2023). Health and well-being through COVID-19 vaccination: Physical, oral, and psychological effects. *International Journal of Environmental Research and Public Health*, 20(4), 3117. DOI: <https://doi.org/10.3390/ijerph20043117>
- Alazzam, F. a. F., Shakatreh, H. J. M., Gharaibeh, Z. I. Y., Aldrou, K. K. a. R., & Alkhatib, A. J. (2022). COVID-19 vaccinations: Medical, ethical and legal aspects. *Medical Archives*, 76(6), 413. DOI: <https://doi.org/10.5455/medarh.2022.76.413-418>
- Alsuwaidi, A. R., Hammad, H. a. A., Elbarazi, I., & Sheek-Hussein, M. (2023). Vaccine hesitancy within the Muslim community: Islamic faith and public health perspectives. *Human Vaccines & Immunotherapeutics*, 19(1). DOI: <https://doi.org/10.1080/21645515.2023.2190716>
- Artenstein, A. W., & Grabenstein, J. D. (2008). Smallpox vaccines for biodefense: Need and feasibility. *Expert Review of Vaccines*, 7(8), 1225-1237. DOI: <https://doi.org/10.1586/14760584.7.8.1225>
- Bohmwald, K., Diethelm-Varela, B., Rodríguez-Guilarte, L., Rivera, T., Riedel, C. A., González, P. A., & Kalergis, A. M. (2024). Pathophysiological, immunological, and inflammatory features of long COVID. *Frontiers in Immunology*, 15. DOI: <https://doi.org/10.3389/fimmu.2024.1341600>
- Cankat, S., Demael, M. U., & Swadling, L. (2023). In search of a pan-coronavirus vaccine: Next-generation vaccine design and immune mechanisms. *Cellular and Molecular Immunology*, 21(2), 103-118. DOI: <https://doi.org/10.1038/s41423-023-01116-8>
- Cerda, A. A., & García, L. Y. (2021). Hesitation and refusal factors in individuals' decision-making processes regarding a coronavirus disease 2019 vaccination. *Frontiers in Public Health*, 9. DOI: <https://doi.org/10.3389/fpubh.2021.626852>
- Chakraborty, C., Bhattacharya, M., & Dhama, K. (2023). SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: The lessons learned might help to fight against the next pandemic. *Vaccines*, 11(3), 682. DOI: <https://doi.org/10.3390/vaccines11030682>
- Chen, C., Hauptert, S. R., Zimmermann, L., Shi, X., Fritsche, L. G., & Mukherjee, B. (2022). Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: A meta-analysis and systematic review. *The Journal of Infectious Diseases*, 226(9), 1593-1607. DOI: <https://doi.org/10.1093/infdis/jiac136>
- Del Cura-Bilbao, A., López-Mendoza, H., Chaure-Pardos, A., Vergara-Ugarriza, A., & Guimbao-Bescós, J. (2022). Effectiveness of 3 COVID-19 vaccines in preventing SARS-CoV-2 infections, January-May 2021, Aragon, Spain. *Emerging Infectious Diseases*, 28(3), 591-598. DOI: <https://doi.org/10.3201/eid2803.212027>
- Faksova, K., Walsh, D., Jiang, Y., Griffin, J., Phillips, A., Gentile, A., Kwong, J., Macartney, K., Naus, M., Grange, Z., Escolano, S., Sepulveda, G., Shetty, A., Pillsbury, A., Sullivan, C., Naveed, Z., Janjua, N., Giglio, N., Perälä, J., . . . Hviid, A. (2024). COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. *Vaccine*. DOI: <https://doi.org/10.1016/j.vaccine.2024.01.100>
- Goldin, S., Moen, A., Moss, W. J., & Nuzzo, J. (2024). The 2020 immunization programme landscape: Piloting an assessment metric to evaluate the maturity of national immunization programmes across the life course. *Vaccine*. DOI: <https://doi.org/10.1016/j.vaccine.2023.12.051>
- Harter, A., Li, X., Echeverria-Londono, S., Roth, J., Abbas, K., Auzenbergs, M., De Villiers, M. J., Ferrari, M. J., Fraser, K., Fu, H., Hallett, T., Hinsley, W., Jit, M., Karachaliou, A., Moore, S. M., Nayagam, S., Papadopoulos, T., Perkins, T. A., Portnoy, A., . . . Gaythorpe, K. a. M. (2024). Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: A modelling study. *The Lancet Global Health*, 12(4), e563-e571. DOI: [https://doi.org/10.1016/s2214-109x\(23\)00603-4](https://doi.org/10.1016/s2214-109x(23)00603-4)
- Hinman, A. (1999). Eradication of vaccine-preventable diseases. *Annual Review of Public Health*, 20(1), 211-229. DOI: <https://doi.org/10.1146/annurev.publhealth.20.1.211>
- Hồ, N. T., Hughes, S. G., Ta, V. T., Phan, L. T., Đỗ, Q., Nguyễn, T. V., Phạm, A. T. V., Đặng, M. T. N., Nguyễn, L. V., Trịnh, Q. V., Phạm, H. N., Chử, M. V., Nguyễn, T. T., Lương, Q. C., Lê, V. T. T., Nguyễn, T. V., Trần, L., Van Luu, A. T., Nguyen, A. N., . . . Nguyen, X. (2024). Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: Pooled phase 1, 2, 3a and 3b randomized, controlled trials. *Nature Communications*, 15(1). DOI: <https://doi.org/10.1038/s41467-024-47905-1>
- Iseron, K. V. (2020). SARS-CoV-2 (COVID-19) Vaccine development and production: An ethical way forward. *Cambridge Quarterly of Healthcare Ethics*, 30(1), 59-68. DOI: <https://doi.org/10.1017/s096318012000047x>
- Jamaludin, S., Azmir, N. A., Ayob, A. F. M., & Zainal, N. (2020). COVID-19 exit strategy: Transitioning towards a new normal. *Annals of Medicine and Surgery*, 59, 165-170. DOI: <https://doi.org/10.1016/j.amsu.2020.09.046>
- Kashte, S., Gulbake, A., El-Amin, S. F., III, & Gupta, A. (2021). COVID-19 vaccines: Rapid development, implications, challenges and future prospects. *Human Cell*, 34(3), 711-733. DOI: <https://doi.org/10.1007/s13577-021-00512-4>
- Koneru, A., Wells, K., Carnes, C. A., Drumhiller, K., Chatham-Stephens, K., Melton, M., Oliphant, H., Hall, S., Dennison, C., Fiscus, M., & Vogt, T. (2024). A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years. *Vaccine*. DOI:

- <https://doi.org/10.1016/j.vaccine.2024.03.064>  
Krammer, F. (2023). The role of vaccines in the COVID-19 pandemic: What have we learned? *Seminars in Immunopathology*. DOI: <https://doi.org/10.1007/s00281-023-00996-2>
- Machekanyanga, Z., Ndiaye, S., Gerede, R., Chindedza, K., Chigodo, C., Shibeshi, M. E., Goodson, J., Daniel, F., Zimmerman, L., & Kaiser, R. (2017). Qualitative assessment of vaccination hesitancy among members of the apostolic church of Zimbabwe: A case study. *Journal of Religion and Health*, 56(5), 1683-1691. DOI: <https://doi.org/10.1007/s10943-017-0428-7>
- Mao, Z., Li, Q., Wang, Y., & Zhou, J. (2024). Pro-religion attitude predicts lower vaccination coverage at country level. *Humanities and Social Sciences Communications*, 11(1). DOI: <https://doi.org/10.1057/s41599-023-02598-7>
- Marks, P., & Califf, R. (2024). Is vaccination approaching a dangerous tipping point? *JAMA*, 331(4), 283. DOI: <https://doi.org/10.1001/jama.2023.27685>
- Mazidimoradi, A., Allahqoli, L., & Salehiniya, H. (2023). The ambiguous future of the COVID-19 pandemic in the presence of a vaccine. *Health Science Reports*, 6(4). DOI: <https://doi.org/10.1002/hsr2.1207>
- Mead, M. N., Seneff, S., Wolfinger, R., Rose, J., Denhaerynck, K., Kirsch, S., & McCullough, P. A. (2024). COVID-19 mRNA vaccines: Lessons learned from the registrational trials and global vaccination campaign. *Cureus*. DOI: <https://doi.org/10.7759/cureus.52876>
- Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., Al-Hashimi, Y. A., Fares, A., Zeghlache, R., & Zakaria, D. (2022). The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: A systematic review. *Human Vaccines & Immunotherapeutics*, 18(1). DOI: <https://doi.org/10.1080/21645515.2022.2027160>
- Mostafa, R. H., & Moustafa, A. (2024). Beyond acute infection: Molecular mechanisms underpinning cardiovascular complications in long COVID. *Frontiers in Cardiovascular Medicine*, 11. DOI: <https://doi.org/10.3389/fcvm.2024.1268571>
- Orenstein, W. A., & Ahmed, R. (2017). Simply put: Vaccination saves lives. *Proceedings of the National Academy of Sciences*, 114(16), 4031-4033. DOI: <https://doi.org/10.1073/pnas.1704507114>
- Park, H. J., Gonsalves, G. S., Tan, S. T., Kelly, J. D., Rutherford, G. W., Wachter, R. M., Schechter, R., Paltiel, A. D., & Lo, N. C. (2024). Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. *Nature Communications*, 15(1). DOI: <https://doi.org/10.1038/s41467-024-45549-9>
- Patryn, R. K., & Zagaja, A. (2016). Vaccinations—Between free will and coercion. *Human Vaccines & Immunotherapeutics*, 12(8), 2204-2205. DOI: <https://doi.org/10.1080/21645515.2016.1162936>
- Pietzner, M., Denaxas, S., Yasmeen, S., Ulmer, M. A., Nakanishi, T., Arnold, M., Kastenmüller, G., Hemingway, H., & Langenberg, C. (2024). Complex patterns of multimorbidity associated with severe COVID-19 and long COVID. *Communications Medicine*, 4(1). DOI: <https://doi.org/10.1038/s43856-024-00506-x>
- Polykretis, P., Donzelli, A., Lindsay, J. C., Wiseman, D., Kyriakopoulos, A. M., Mörz, M., Bellavite, P., Fukushima, M., Seneff, S., & McCullough, P. A. (2023). Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues. *Autoimmunity*, 56(1). DOI: <https://doi.org/10.1080/08916934.2023.2259123>
- Prasad, V., & Haslam, A. (2024). COVID-19 vaccines: History of the pandemic's great scientific success and flawed policy implementation. *Bioethics News*. DOI: <https://doi.org/10.1007/s40592-024-00189-z>
- Rahmani, K., Shavaleh, R., Forouhi, M., Disfani, H. F., Kamandi, M., Oskooi, R. K., Foogardi, M., Soltani, M., Rahchamani, M., Mohaddespour, M., & Dianatinasab, M. (2022). The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. *Frontiers in Public Health*, 10. DOI: <https://doi.org/10.3389/fpubh.2022.873596>
- Rana, R., Kant, R., Kumra, T., Gupta, S., Rana, D. S., & Ganguly, N. K. (2023). An update on SARS-CoV-2 immunization and future directions. *Frontiers in Pharmacology*, 14. DOI: <https://doi.org/10.3389/fphar.2023.1125305>
- Rashi, T. (2023). Priority of vaccination of the population against COVID-19: Moral principles. *Vaccines*, 11(2), 380. DOI: <https://doi.org/10.3390/vaccines11020380>
- Rodriguez-Morales, A. J., Lopez-Echeverri, M. C., Perez-Raga, M. F., Quintero-Romero, V., Valencia-Gallego, V., Galindo-Herrera, N., López-Alzate, S., Sánchez-Vinasco, J. D., Gutiérrez-Vargas, J. J., Mayta-Tristan, P., Husni, R., Moghnieh, R., Stephan, J., Faour, W., Tawil, S., Barakat, H., Chaaban, T., Megarbane, A., Rizk, Y., . . . Ulloa-Gutiérrez, R. (2023). The global challenges of the long COVID-19 in adults and children. *Travel Medicine and Infectious Disease*, 54, 102606. DOI: <https://doi.org/10.1016/j.tmaid.2023.102606>
- Šalamon, Š., Ewing, A., Fox, G., Bilodeau, S., Gershenson, C., Heino, M. T., & Bar-Yam, Y. (2024). SARS-CoV-2 and COVID-19: From crisis to solution. *WHN Science Communications*, 5(1), 1. DOI: <https://doi.org/10.59454/whn-2401-334>
- Seyedin, H., Zanganeh, A., Mojtabaei, M., Bagherzadeh, R., & Faghihi, H. (2020). A model of reopening business to decrease the health and economic impacts of the COVID-19 pandemic: Lessons from Iran. *The Medical Journal of the Islamic Republic of Iran*, 34(1), 97. DOI: <https://doi.org/10.34171/mjiri.34.97>
- Shi, T., Robertson, C., & Sheikh, A. (2023). Effectiveness and safety of coronavirus disease 2019 vaccines. *Current Opinion in Pulmonary Medicine*, 29(3), 138-142. DOI: <https://doi.org/10.1097/mcp.0000000000000948>
- Srivastava, K., Carreño, J. M., Gleason, C., Monahan, B., Singh, G., Abbad, A., Tcheou, J., Raskin, A., Kleiner, G., Van Bakel, H., Sordillo, E. M., Krammer, F., Simon, V., Alshammry, H., Amoako, A. A., Andre, D., Awawda, M., Bermúdez-González, M. C., Beach, K. F., . . . Wajnberg, A. (2024). SARS-CoV-2-infection and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. *Immunity*, 57(3), 587-599.e4.

- DOI: <https://doi.org/10.1016/j.immuni.2024.01.017>
- Stoddard, M., Sarkar, S., Yuan, L., Nolan, R. P., White, D. E., White, L. F., Hochberg, N. S., & Chakravarty, A. (2021). Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. *PLoS ONE*, 16(7), e0254734. DOI: <https://doi.org/10.1371/journal.pone.0254734>
- Unfried, K., & Priebe, J. (2024). Vaccine hesitancy and trust in sub-Saharan Africa. *Scientific Reports*, 14(1). DOI: <https://doi.org/10.1038/s41598-024-61205-0>
- Wu, N., Joyal-Desmarais, K., Ribeiro, P. a. B., Vieira, A. M., Stojanovic, J., Sanuade, C., Yip, D., & Bacon, S. L. (2023). Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: Findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. *The Lancet Respiratory Medicine*, 11(5), 439-452. DOI: [https://doi.org/10.1016/s2213-2600\(23\)00015-2](https://doi.org/10.1016/s2213-2600(23)00015-2)
- Yoder, J. S., & Dworkin, M. S. (2006). Vaccination usage among an old-order Amish community in Illinois. *The Pediatric Infectious Disease Journal*, 25(12), 1182-1183. DOI: <https://doi.org/10.1097/01.inf.0000246851.19000.3e>
- Zhang, Y., Bharathi, V., Dokoshi, T., De Anda, J., Ursery, L. T., Kulkarni, N. N., Nakamura, Y., Chen, J., Luo, E. W. C., Wang, L., Xu, H., Coady, A., Zurich, R., Lee, M. W., Matsui, T., Lee, H., Chan, L. C., Schepmoes, A. A., Lipton, M. S., . . . Wong, G. C. L. (2024). Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes. *Proceedings of the National Academy of Sciences*, 121(6). DOI: <https://doi.org/10.1073/pnas.2300644120>
- Zheng, Y., Zeng, N., Yuan, K., Tian, S., Yang, Y., Gao, N., Chen, X., Zhang, A., Kondratiuk, A. L., Shi, P., Zhang, F., Sun, J., Yue, J., Lin, X., Shi, L., Lalvani, A., Shi, J., Bao, Y., & Lu, L. (2023). Prevalence and risk factor for long COVID in children and adolescents: A meta-analysis and systematic review. *Journal of Infection and Public Health*, 16(5), 660-672. DOI: <https://doi.org/10.1016/j.jiph.2023.03.005>

---

Received: August 27, 2024 | Revised: September 18, 2024 | Accepted: September 19, 2024

---